Pharma can provide clinical support for chronic disease programs

Edlin, Mari
October 2010
Managed Healthcare Executive;Oct2010, Vol. 20 Issue 10, p23
Trade Publication
The article focuses on the significant role played by pharmacies in providing clinical support for chronic disease programs in the U.S. According to Paul Setlak of Abbott Laboratories Inc., a valuable asset can be provided by drug companies to managed care organizations (MCOs). It cites disease programs supported by pharmacies such as Pfizer Inc.'s Depression Benchmarks and Daiichi Sankyo Inc.'s Under Pressure.


Related Articles

  • MID program saves $28.5 million over 2 years.  // PharmacoEconomics & Outcomes News;2/19/2011, Issue 622, p6 

    The article reports on a study published in the "Journal of Managed Care Pharmacy" which revealed the cost savings provided by a Medical Injectable Drug (MID) program introduced into a managed care organisation in the U.S.

  • Execs Expect Population Health Management ROI in 3-4 Years. Goth, Greg // Healthdatamanagement.com;1/19/2015, p4 

    The article reports that over half of U.S. healthcare managers expected to recover their investments in population health management programs in three to four years as of 2015. Topics covered include how population health management programs reduce variability in care and avoidable medical...

  • Research & Markets: Managed Care and the Pharmaceutical Industry - Top Issues, Health Care Reform and the Inter-linkages Bringing Them Together.  // Biomedical Market Newsletter;3/31/2011, p369 

    The article provides an overview of the top issues in the managed care market and examines how pharmaceutical industry affects the growth of managed care in the U.S. market. It reveals that both industries have invested in the research and development of disease management and medication...

  • CARDIOVASCULAR SYSTEM 9A.  // MPR - Urologists' Edition;Spring/Summer2012, Vol. 9 Issue 1, p86 

    The article offers brief information on several drugs to treat cardiovascular diseases including Accupril tablets from Pfizer Inc., Atacand tablets from AstraZeneca PLC and Benicar from Daiichi Sankyo Inc.

  • Doctor's Choice hands outhonors. M .A. // Medical Marketing & Media;Dec2006, Vol. 41 Issue 12, p18 

    The article announces awards given to Fosamax advertisement of Merck & Co. Inc., Evoxac advertisement of Daiichi Sankyo, and the Zyvox advertisements of Pfizer Inc. during the Doctors' Choice Awards. The Fosamax campaign won the generalist physician category. Meanwhile, the Evoxac advertisement...

  • Kejjer Heads Daiichi Sanyko Commercial Operations.  // Chain Drug Review;5/19/2014, Vol. 36 Issue 8, p65 

    The article announces several personnel changes at health care firms including appointments of Ken Keller as the president of commercial operations at Daiichi Sankyo Inc., Ian Read as chairman of Pfizer Inc, and G. Frederick Wilkinson as president of Impax Laboratories Inc.

  • Cardiovascular News Round-Up.  // PharmaWatch: Monthly Review;May2010, Vol. 9 Issue 5, p9 

    The article offers world news briefs related to the treatment of cardiovascular diseases. Abbott Laboratories Inc. has reported positive 30-day results from the second phase of its Absorb trial. A new drug application has been filed by Daiichi Sankyo Co. Ltd. in Japan for the approval of...

  • Accountable Care Organizations: The Missing Link to Engagement in Health and Health Care? Halterman, Steven L.; Balezentis, Melinda S. // Benefits Quarterly;2015 Third Quarter, Vol. 31 Issue 3, p29 

    Accountable care organizations (ACOs) aim to transform health care delivery and provider payment in a way that improves patient access, engagement and quality of care. If successful, ACOs may help the U.S. health care system finally evolve from a "diagnose, treat and reimburse mostly acute,...

  • Supplier Sales and Earnings: 2015 Second Quarter.  // Chain Drug Review;9/14/2015, Vol. 37 Issue 14, p16 

    A chart is presented depicting sales and earnings of several drug firms including Abbott Labs, AstraZeneca and Pfizer, as of second quarter of 2015.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics